In the article "Progressive dialysis encephalopathy" (Ann Neurol ~4 : 199-204, 1 9 7 8 ) , Drs Lederman and Henry considered the role of aluminum in the origin of dialysis encephalopathy 3s speculative. W-e were astonished that aluminum blood levels were not reported for their 9 patients.
triphasic spike conhgurations were noted. T h e average serum aluminum level was 407 pg per liter in the acute phase, 161 pg per liter in the remission phase with an average delay of six weeks, and 123 pg per liter three months later with maintained remission. ( T h e normal serum aluminum level i s 4 0 pg per liter as determined by flameless-oven atomic sl-'ectrophotometry. ) Following interruption of the oral and ilidysate aluminum intake, remissions were permanently mainrained. In 2 cases, transient oral readministration o f aluminum to treat hyperphosphatemia was followed 13, recurrent encephalopathy, reversed only when aluminum intake was stopped again. We analyzed data from a small dialysis unit on 8 patients who developed typical progressive dialysis encephalopathy with fatal outcome 161. These 8 patients represented a 38cf incidence during the 22-month period in which aluminum was added to city water at concentrations of 200 to 1,000 pg per liter. In contrast, the incidence of this syndrome was zero for the five preceding years when no aluminum was added to the water ( p < 0.05 for difference in incidence).
Ref
During three years after a deionizer was installed that lowered the aluminum content to less than 1 pg per liter, no case suggesting this encephalopathy was observed, giving again a significantly lower incidence (p < 0.0002) [ 5 ] .
T h e etiological importance of p a r e n t e d aluminum ad- A very effective drug in migraine prophylaxis is methysergide, a putative serotonin antagonist. Methysergide has been shown to antagonize the analgesia produced by microinjection of opiates into the midbrain periaqueductal gray matter. Like lysergic acid diethylamide, which has been shown to antagonize analgesia produced by electrical stimulation of the PAG, methysergide inhibits spontaneous firing of serotoninergic raphe neurons when applied iontophoretically [ 2 ] . Thus, an alternative explanation for the counteraction of opiate analgesia by methysergide can be found in the inhibition of raphe neurons which mediate both opiate analgesia and stimulation-produced analgesia. The difference in mode and possibly site of action between methysergide and pCPA may account for the fact that, although both drugs turn off the "erroneously" activated pain-suppression system in migraineurs, spontaneous pains have not been reported for methysergide. When the pain-suppression system is put at rest, it may come into action at appropriate times and cope with a process which may otherwise result in a devastating headache.
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